NL-OMON46604招募中不适用
A randomized, double-blind, placebo-controlled, single dose, 3-way cross-over study in healthy elderly subjects to develop an anti-cholinergic pharmacological challenge with biperiden. - Biperiden challenge study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Elderly male or female subjects aged between 65 and 80 (inclusive) years old;
- •2. Healthy subjects as defined by the absence of evidence of any active or chronic disease following detailed medical and surgical history review and a complete physical examination including vital signs, 12-lead ECG, haematology, blood chemistry, and urinalysis;
- •3. BMI between 18 and 34 kg/m2, inclusive;
- •4. Female subjects should be postmenopausal. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level at screening (>40 IU/L or mIU/mL) in the postmenopausal range may be used to confirm a postmenopausal state in women.
- •5. Able to understand the commitments of the study and to communicate effectively with the investigator and site staff;
- •6. Absence of cognitive impairment evident by a score of 28 or higher on the Mini Mental State Examination (MMSE);
- •7. Able to participate and willing to give written informed consent and to comply with the study restrictions.
排除标准
- •1. Clinically relevant history of abnormal physical or mental health interfering with the study as determined from the medical history review and the physical examinations obtained during the screening visit and/or at the start of the first study day for each period as judged by the investigator (including (but not limited to), neurological, psychiatric, endocrine, cardiovascular (including recent myocardial infarction), respiratory, gastrointestinal, hepatic, renal disorder or presence of narrow-angle glaucoma).
- •2. History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drugs.
- •3. Any disease associated with cognitive impairment, including but not limited to schizophrenia and dementia.
- •4. History of severe allergies, or history of an anaphylactic reaction to prescription or non-prescription drugs or food.
- •5. History of hypersensitivity to biperiden or to the excipients used in the biperiden formulation (Maize starch, Lactose monohydrate, Microcrystalline cellulose, Calcium hydrogen phosphate, Copovidone, Talc, Magnesium stearate, Potato starch)
- •6. Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
- •7. Positive urine drug screen (UDS), or alcohol test at screening and/or upon admission to the Clinical Research Unit (CRU).
- •8. 8. Presence or history (within 3 months of screening) of alcohol abuse confirmed by medical history, or daily alcohol consumption exceeding 2 standard drinks per day on average for females or exceeding 3 standard drinks per day on average for males (1 standard drink = 10 grams of alcohol), and the inability to refrain from alcohol during the visits until discharge from the CRU (alcohol consumption will be prohibited during study confinement).
- •9. Use of tobacco and/or nicotine-containing products within 90 days of dosing and throughout the study until follow-up.
- •10. 10. Excessive caffeine consumption, defined as >800 mg per day from 7 days prior to the first dose of the study drug until 24 hours prior to dosing. Subjects will abstain from caffeine-containing products for 24 hours prior each dosing and whilst in the study unit until discharge from the study unit. At other times throughout the study, subjects should not consume more than 800 mg caffeine per day. Caffeine quantities defined as: one cup of coffee contains 100 mg of caffeine; one cup of tea, or one glass of cola, or potion of chocolate (dark:100 g, milk 200 g) contains approximately 40 mg of caffeine; one bottle of Red Bull contains approximately 80 mg of caffeine.
- •11. Any other concurrent disease or condition that could interfere with, or for which the concomitant treatment might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study.
- •12. Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug or more than 4 times per year.
- •13. Donation or loss of blood of more than 500 mL within 3 months (males) or 4 months (females) prior to screening.
- •14. Use of concomitant medications within 14 days prior to study drug administration or within 5 half-live (whichever is longer). For details see section 4.4.
研究者
相似试验
未知
Unknown
A single intravenous dose study of E3112 in Japanese healthy adult male subjectsHealthy Adult SubjectsJPRN-jRCT2080223364EA Pharma Co.,Ltd.40
进行中（未招募）
1 期
The pain reduction effects of different doses of Lopain (MTX-071) relative to placebo are evaluated in patients with chronic osteoarthritic knee joint pain.chronic osteoarthritic knee joint painMedDRA version: 21.1Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859MedDRA version: 20.0Level: LLTClassification code 10003244Term: Arthritic painsSystem Organ Class: 100000004859MedDRA version: 20.0Level: LLTClassification code 10064238Term: GonalgiaSystem Organ Class: 100000004859EUCTR2018-000818-37-HRMestex AG156
已完成
不适用
Phase I Clinical Study to Evauate the Tolerability and Pharmacokinetics of Belviq in Healthy Korean volunteersKCT0001063Ildong pharmaceutical24
已完成
不适用
A randomized, double-blind, placebo-controlled, single ascending dose and multiple dose study to evaluate the safety, tolerability and pharmacokinetics of Cannabidiol (GWP42003-P) oral liquid formulation with an open label two-period cross-over part to study food effects in healthy subjectsEpilepsyNL-OMON42686GW Research Ltd.56
进行中（未招募）
1 期
A trial to evaluate the safety, tolerability, and pharmacokinetics of AQ280 in healthy subjectsAllergic reaction in the gulletDigestive Systemeosinophilic esophagitis (EoE)ISRCTN14453297Aqilion AB64